

REMARKS

By this amendment, the paragraph in the specification entitled "Antibody", which begins on page 53 at line 23 and ends on page 54 at line 10, has been replaced with a replacement paragraph in which the sequences given in the paragraph are correctly identified by the corresponding SEQ ID NOS. 41 and 42, rather than 31 and 32. Applicant submits that in the US application as filed, the designations "SEQ ID NO: 31" and "SEQ ID NO: 32" were inadvertently used twice in the specification. (See page 43, lines 25 and 26). By changing the phrases "SEQ ID NO: 31" and "SEQ ID NO: 32" in the aforementioned paragraph to "SEQ ID NO: 41" and "SEQ ID NO: 42" this duplication is corrected. The references to sequences in the specification, as amended, are consistent with the Sequence Listing which is concurrently filed herewith.

Applicant submits that this amendment does not add any new matter to the application, and respectfully requests entry of the amendment.


Formal Matters and Conclusion

The Examiner is respectfully requested to examine and pass the above application to issue at the earliest possible time.

Should the Examiner find the application to be other than in condition for allowance, the Examiner is requested to contact the undersigned at the local telephone number listed below to discuss any other changes deemed necessary in a telephonic or personal interview.

Please charge any underpayment or credit any overpayment of fees to attorney's deposit account #50-2041.

Respectfully submitted,


Ruth E. Tyler-Cross
Reg. No. 45,922

Whitham, Curtis & Christofferson
11491 Sunset Hills Road; Suite 340
Reston, VA 20190
703-787-9400